HealthInvestor Asia Summit 2018
Financial intelligence for Asia's healthcare markets
Remember me:

Analysis: Healthcare m&a to jump 80% in 2018

After a subdued 2017, healthcare mergers & acquisitions are expected to jump more than 80% this year in Asia Pacific to US$55.1 billion, according to global law firm Baker McKenzie.

Uncertainty in the wake of Brexit, the US presidential election and pending US tax reform cooled healthcare m&a activity in 2017. In 2018, however, Baker McKenzie is forecasting that current buoyant market conditions and clarity about the US’s new corporate tax rate will lead to a rebound in deal activity, causing global healthcare m&a to rise to US$418 billion, up 50% from US$277 billion last year.

In Asia Pacific, a major driver of m&a transactions continues to be big pharma buying manufacturing sites in lower cost jurisdictions like Vietnam and India. Pharma companies are also acquiring local companies for their distribution networks in emerging markets like China to gain access to the growing middle class that now has disposable income to spend on healthcare.

The total value of IPOs in the healthcare sector rose to US$15.7 billion in 2017, boosted by Chinese drug r&d company WuXi Biologics’ debut on the Hong Kong Stock Exchange in June, which raised more than US$580 million. In 2018, it forecasts healthcare IPOs to become even more active, rising to US$22.3 billion globally.

“We’re seeing a lot of biotechs get to the point where they need more capital for R&D and they’re debating whether to raise capital through an IPO or just sell the business now to take advantage of all-time high valuations,” said Tom Rice, a Baker McKenzie securities partner based in New York. “As a result, we’ve seen a resurgence over the last year or so of dual-track IPO sale processes seeking to maximise value.”

Healthtech companies are also likely to pursue IPOs to raise capital for R&D and to manufacture and open up new distribution channels for their products.

“The healthcare IPO market is beginning to gain surer footing as IPO valuations become more competitive with m&a,” said Ashok Lalwani, head of Baker McKenzie’s international capital markets practice in Asia Pacific. “As IPO valuations rise, we should start to see more of a trend towards companies using IPOs as an exit route as opposed to a trade sale.”

Following a peak in deal activity in 2018, the Baker McKenzie’s Global Transactions Forecast, developed in association with Oxford Economics, forecasts that healthcare m&a and IPO transactions will decline in 2019 in line with a larger, worldwide trend of cooling deal activity in developed markets. “As interest rates rise, global trade and investment growth slows, and equity prices correct, we forecast healthcare m&a to drop modestly to US$414 billion in 2019, and further to US$368 billion in 2020,” it said.

After reaching a five-year high of US$22.3 billion in 2018, IPOs in the healthcare sector are expected to drop slightly to US$21.4 billion in 2019 before declining further to US$17.7 billion in 2020.

Posted on: 11/01/2018 UTC+08:00


Australian medtech company Medibio has signed a strategic partnership agreement with health technology services company Striiv.
Spanish molecular diagnostics company Genomica has opened its first subsidiary in Wuhan, China. The office, established in the East Lake High Tech Zone, will serve as an operations centre to increase the presence of the it parent, the PharmaMar Group not only in China, but also in other Asian-Pacific countries.
Shanghai-based mobile social platform The CareVoice, which is focused on the insurance industry, has raised US$2 million in its third round of seed funding led by venture capital firms SOSV and Haitao Capital.
Archie Fraser has stepped down as chief executive of Optiscan Imaging, which develops microscopic imaging technologies for medical markets, effective immediately. No reason for his resignation has been given.
Simon Lipscombe has resigned from his position as CEO of New Zealand’s Green Cross Health’s community health division. He has accepted the position of managing director of the New Zealand subsidiary of Compass Group, the world’s leading food and support services company.
Malaysian multinational PRG Holdings is moving into healthcare with the proposed acquisition of O&G focused private medical services provider Roopi Medical Centre for M$18.3 million (US$4.6 million) and a 25% stake in Esther Postpartum for M$3.75 million.
Union Medical Healthcare, the largest aesthetic medical service provider in Hong Kong, has mandated CMB International Capital as sole global coordinator and joint bookrunner with UBS and Haitong International to sell US dollar Reg S bonds.
It should surprise no one that the over-allotment option has been fully exercised by China Merchants Securities for Hong Kong ophthalmic company C-Mer Eye Care Holdings.


The healthcare industry in Asia-Pacific is expected to grow at 11.1% in 2018, representing one of the fastest growing regions in the world, as the global healthcare economy averages a 4.8% annual growth rate.
Technologist, business leader, and philanthropist Bill Gates explains why global health needs the private sector.
Mitch Beaumont, Prashanth Prasad, Ulrica Sehlstedt and Mandeep Dhillon from international management consultants Arthur D. Little explain how medical technology companies can manage going digital.
Susann Roth, senior social development specialist, Asian Development Bank, argues why a health impact assessment is essential for hard infrastructure projects.
After a subdued 2017, healthcare mergers & acquisitions are expected to jump more than 80% this year in Asia Pacific to US$55.1 billion, according to global law firm Baker McKenzie.
After the Hong Kong High court found a doctor and a lab technician guilty of manslaughter, Michael Griffiths, regional director of healthcare at specialist insurance brokers Howden, looks at the extent of insurance or indemnity available to doctors in Asia accused of criminal acts.
Susann Roth, senior social development specialist, Asian Development Bank, looks at how Vietnam is building its digital health capacity.
The world’s first healthcare development impact bond aimed at reducing the number of maternal and newborn deaths in Rajasthan, India, launched last week.
my images


Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices